Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mayzent

Biogen Idec building

Biogen multiple sclerosis drug flunks clinical trial

Opicinumab had been proposed as a possible reparative therapy in MS

- PMLiVE

GSK brings forward triple COPD therapy filing in US

Intends to file the three-drug respiratory therapy by the end of 2016

- PMLiVE

Sanofi Genzyme launches multiple sclerosis awareness campaign

Aims to highlight and address the physical and emotional burden of the disease

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

Novartis building

Novartis says Cosentyx is ‘outpacing competitors’

Claims new psoriasis drug has almost a third of the market share in Germany alone

Novartis Gehry Building

Novartis pushes the accelerator with new Entresto trials

Looks to kick-start sales of its heart failure drug with new study programme

- PMLiVE

Novartis funds chronic urticaria app and patient community

My Hives has been developed, and will be run, by Exco InTouch

Novartis day

Trial sets up showdown between Ibrance and Novartis’ ribociclib

Positive interim data could put the Swiss firm's breast cancer therapy in-line for early approval

Novartis building

Novartis splits pharma unit as Epstein exits

Restructure sees creation of standalone cancer arm Novartis Oncology

EISAI

Eisai gets green light for Lenvima in kidney cancer

New drug awarded breakthrough and priority review status by FDA in RCC

Eli Lilly HQ

Lilly’s psoriasis drug Taltz cleared in Europe

Clinicians suggest the IL-17 inhibitor has “best-in-class data”

Novartis building

As promised, Novartis’ Entresto is a ‘slow burner’

Inverts typical sales pattern with faster uptake of the drug in Europe than in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links